BCYC insider trading

Healthcare

BICYCLE THERAPEUTICS PLC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
434
Last 90 days
11
Buys / sells
5% / 53%
Market cap
$357.59M

About BICYCLE THERAPEUTICS PLC

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Company website: www.bicycletherapeutics.com

BCYC insider activity at a glance

FilingIQ has scored 434 insider transactions for BCYC since May 27, 2019. The most recent filing in our index is dated Apr 6, 2026.

Across the full history, 21 open-market purchases and 229 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BCYC insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Other Healthcare tickers with recent insider activity

Frequently asked

How many insider trades does FilingIQ track for BCYC?
FilingIQ tracks 434 Form 4 insider transactions for BCYC (BICYCLE THERAPEUTICS PLC), covering filings from May 27, 2019 onwards. 11 of those were filed in the last 90 days.
Are BCYC insiders net buyers or net sellers?
Across the full Form 4 history for BCYC, 21 transactions (5%) were open-market purchases and 229 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BCYC insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BCYC in?
BICYCLE THERAPEUTICS PLC (BCYC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $357.59M.

Methodology & sources

Every BCYC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.